Is there a correlation between pathologically confirmed focal nodular hyperplasia (FNH) of the liver and an elevated CA 19-9 level in a 40-year-old woman?

No Established Correlation Between FNH and Elevated CA 19-9

Focal nodular hyperplasia (FNH) is a benign hepatic lesion that does not cause elevation of CA 19-9; the markedly elevated CA 19-9 level of 339 U/mL in this patient requires investigation for alternative causes, particularly cholangiocarcinoma or other hepatobiliary malignancies.

Understanding the Disconnect

FNH Characteristics

FNH is a benign hyperplastic response to vascular anomalies in the liver 1, 2, 3. It:

• Occurs predominantly in young women (though no clear sex predilection exists) 4
• Is typically asymptomatic and discovered incidentally 4, 5
• Has no malignant potential 3, 6
• Does not produce tumor markers

CA 19-9 Elevation: What It Actually Indicates

CA 19-9 is not specific for any single malignancy and is elevated in 7:

• Cholangiocarcinoma (up to 85% of cases)
• Pancreatic cancer
• Gastric malignancy
• Biliary obstruction (benign or malignant)
• Severe hepatic injury from any cause
• Inflammatory bowel disease

Critical point: A CA 19-9 level of 339 U/mL is significantly elevated (>100 U/mL threshold has 75% sensitivity and 80% specificity for cholangiocarcinoma in PSC patients) 7.

What This Patient Needs

Immediate Evaluation Required

With pathologically confirmed FNH and CA 19-9 of 339 U/mL, you must:

1. Rule out concurrent cholangiocarcinoma or other malignancy

   • High-quality contrast-enhanced MRI with MRCP 8, 9
   • Evaluate for biliary strictures, mass lesions, or vascular involvement
   • Assess for intrahepatic or perihilar tumors that may have been missed

2. Assess for biliary obstruction

   • Check liver function tests (alkaline phosphatase, bilirubin, GGT) 7
   • CA 19-9 can be elevated in benign biliary obstruction, but persistently elevated levels after decompression suggest malignancy 7
   • Rule out bacterial cholangitis (which also elevates CA 19-9) 10, 8

3. Consider other gastrointestinal malignancies

   • CA 19-9 does not discriminate between cholangiocarcinoma, pancreatic, or gastric cancer 7
   • Thoraco-abdomino-pelvic CT if not already performed 9

Important Caveats

• 10% of the population is Lewis antigen-negative and cannot produce CA 19-9 11, 9 - this patient clearly can produce it
• The FNH itself is not the source of the elevated CA 19-9
• Do not attribute the CA 19-9 elevation to FNH and miss a concurrent malignancy

Clinical Algorithm

For this 40-year-old woman with confirmed FNH and CA 19-9 339 U/mL:

→ Check liver function tests and rule out cholangitis

• If cholangitis present: treat and recheck CA 19-9 after resolution

→ Obtain contrast-enhanced MRI with MRCP 8, 9

• Look specifically for biliary strictures, mass lesions, or vascular involvement
• Evaluate entire biliary tree and liver parenchyma

→ If imaging shows suspicious findings:

• ERCP with brush cytology/biopsy 8
• Consider FISH analysis if available 10
• Multidisciplinary evaluation at specialized center 8

→ If imaging is negative:

• Repeat CA 19-9 in 1-3 months
• If persistently elevated without explanation, consider ERCP with tissue sampling
• Serial imaging every 3 months until explanation found 8

Bottom Line

The FNH and elevated CA 19-9 are coincidental findings, not causally related. The elevated CA 19-9 demands thorough investigation for cholangiocarcinoma or other hepatobiliary/gastrointestinal malignancy, regardless of the benign FNH diagnosis. Do not be falsely reassured by the pathologically confirmed FNH - these are two separate issues requiring independent evaluation.